These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28893366)

  • 21. Effects of surotomycin on Clostridium difficile viability and toxin production in vitro.
    Bouillaut L; McBride S; Sorg JA; Schmidt DJ; Suarez JM; Tzipori S; Mascio C; Chesnel L; Sonenshein AL
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4199-205. PubMed ID: 25941230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
    Garneau JR; Valiquette L; Fortier LC
    BMC Infect Dis; 2014 Jan; 14():29. PubMed ID: 24422950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carvacrol reduces Clostridium difficile sporulation and spore outgrowth in vitro.
    Mooyottu S; Flock G; Venkitanarayanan K
    J Med Microbiol; 2017 Aug; 66(8):1229-1234. PubMed ID: 28786786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.
    Knight DR; Giglio S; Huntington PG; Korman TM; Kotsanas D; Moore CV; Paterson DL; Prendergast L; Huber CA; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV
    J Antimicrob Chemother; 2015 Nov; 70(11):2992-9. PubMed ID: 26221017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
    Koon HW; Ho S; Hing TC; Cheng M; Chen X; Ichikawa Y; Kelly CP; Pothoulakis C
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4642-50. PubMed ID: 24890583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
    Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
    J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of the MICs of fidaxomicin and other antibiotics against Hungarian Clostridium difficile isolates.
    Eitel Z; Terhes G; Sóki J; Nagy E; Urbán E
    Anaerobe; 2015 Feb; 31():47-9. PubMed ID: 25139122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
    Leeds JA; Sachdeva M; Mullin S; Barnes SW; Ruzin A
    J Antimicrob Chemother; 2014 Jan; 69(1):41-4. PubMed ID: 23887866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
    Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH
    J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution.
    Wolfe C; Pagano P; Pillar CM; Shinabarger DL; Boulos RA
    Diagn Microbiol Infect Dis; 2018 Nov; 92(3):250-252. PubMed ID: 30042035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile.
    Hamada M; Yamaguchi T; Ishii Y; Chono K; Tateda K
    J Infect Chemother; 2020 Jul; 26(7):685-692. PubMed ID: 32224190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity of fidaxomicin against Clostridium difficile clinical isolates in Aichi area in Japan.
    Yamagishi Y; Nishiyama N; Koizumi Y; Matsukawa Y; Suematsu H; Hagihara M; Katsumata K; Mikamo H
    J Infect Chemother; 2017 Oct; 23(10):724-726. PubMed ID: 28527649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of fidaxomicin for the treatment of Clostridium difficile infection.
    Juang P; Hardesty JS
    J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB.
    Schwanbeck J; Riedel T; Laukien F; Schober I; Oehmig I; Zimmermann O; Overmann J; Groß U; Zautner AE; Bohne W
    J Antimicrob Chemother; 2019 Jan; 74(1):6-10. PubMed ID: 30247587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
    Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM; Spooner LM
    Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.